Drugs / OBI-833
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06490198 | Jul 2024 → Jul 2026 overdue | cholangiocarcinoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02310464 | Dec 2015 → Dec 2020 | breast cancer, colorectal cancer, gastric cancer, lung cancer | OBI Pharma, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05442060 | Jul 2022 → Dec 2025 overdue | non-small cell lung carcinoma | OBI Pharma, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05376423 | Jun 2022 → Dec 2024 | esophageal cancer | National Taiwan University Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-11-23 | OBI Pharma, Inc | Results ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine obipharma.com ↗
OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial |
| 2020-11-19 | OBI Pharma, Inc | Results OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine obipharma.com ↗
In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05442060 ↗ |
| Modality | Vaccine | “The investigational therapy, OBI-833, is a glycoconjugate vaccine targeting Globo H” NCT06490198 ↗ |
| Route | Subcutaneous | “given a total of 10 doses of OBI-833/OBI-821 subcutaneously” NCT02310464 ↗ |